320 related articles for article (PubMed ID: 36669489)
1. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control.
Concannon K; Morris BB; Gay CM; Byers LA
Mol Cell; 2023 Mar; 83(5):660-680. PubMed ID: 36669489
[TBL] [Abstract][Full Text] [Related]
2. Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escape.
Qiu Y; Hu X; Zeng X; Wang H
Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(11):1569-1576. PubMed ID: 36305726
[TBL] [Abstract][Full Text] [Related]
3. Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and Protons.
Bright SJ; Flint DB; Martinus DKJ; Turner BX; Manandhar M; Ben Kacem M; McFadden CH; Yap TA; Shaitelman SF; Sawakuchi GO
Radiat Res; 2022 Oct; 198(4):336-346. PubMed ID: 35939823
[TBL] [Abstract][Full Text] [Related]
4. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
Shi C; Qin K; Lin A; Jiang A; Cheng Q; Liu Z; Zhang J; Luo P
J Exp Clin Cancer Res; 2022 Sep; 41(1):268. PubMed ID: 36071479
[TBL] [Abstract][Full Text] [Related]
5. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation.
Hu M; Zhou M; Bao X; Pan D; Jiao M; Liu X; Li F; Li CY
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33290271
[TBL] [Abstract][Full Text] [Related]
6. Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic.
Priya B; Ravi S; Kirubakaran S
Drug Discov Today; 2023 Aug; 28(8):103662. PubMed ID: 37302542
[TBL] [Abstract][Full Text] [Related]
7. Targeting ATR in Cancer Medicine.
Salguero C; Valladolid C; Robinson HMR; Smith GCM; Yap TA
Cancer Treat Res; 2023; 186():239-283. PubMed ID: 37978140
[TBL] [Abstract][Full Text] [Related]
8. Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity.
Zheng S; Song J; Linghu D; Yang R; Liu B; Xue Z; Chen Q; Liu C; Zhong D; Hung MC; Sun L
Int J Biol Sci; 2023; 19(3):981-993. PubMed ID: 36778120
[TBL] [Abstract][Full Text] [Related]
9. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.
Lamberti G; Andrini E; Sisi M; Federico AD; Ricciuti B
Future Oncol; 2020 Aug; 16(23):1751-1766. PubMed ID: 32539551
[TBL] [Abstract][Full Text] [Related]
10. DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression.
Jun DW; Hwang M; Kim YH; Kim KT; Kim S; Lee CH
Oncotarget; 2016 Apr; 7(14):17699-710. PubMed ID: 26848527
[TBL] [Abstract][Full Text] [Related]
11.
Rafiei S; Fitzpatrick K; Liu D; Cai MY; Elmarakeby HA; Park J; Ricker C; Kochupurakkal BS; Choudhury AD; Hahn WC; Balk SP; Hwang JH; Van Allen EM; Mouw KW
Cancer Res; 2020 Jun; 80(11):2094-2100. PubMed ID: 32127357
[TBL] [Abstract][Full Text] [Related]
12. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
[TBL] [Abstract][Full Text] [Related]
13. Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors.
Yu X; Zhu L; Wang T; Li L; Liu J; Che G; Zhou Q
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188910. PubMed ID: 37172653
[TBL] [Abstract][Full Text] [Related]
14. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
Gulliver C; Hoffmann R; Baillie GS
Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
[TBL] [Abstract][Full Text] [Related]
15. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
16. Targeting the DNA damage response in oncology: past, present and future perspectives.
Basu B; Yap TA; Molife LR; de Bono JS
Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
[TBL] [Abstract][Full Text] [Related]
17. The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers.
Zhu L; Liu J; Chen J; Zhou Q
J Hematol Oncol; 2021 Dec; 14(1):206. PubMed ID: 34930377
[TBL] [Abstract][Full Text] [Related]
18. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
[TBL] [Abstract][Full Text] [Related]
19. Interfaces between cellular responses to DNA damage and cancer immunotherapy.
Pilger D; Seymour LW; Jackson SP
Genes Dev; 2021 May; 35(9-10):602-618. PubMed ID: 33888558
[TBL] [Abstract][Full Text] [Related]
20. Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.
Huang JL; Chang YT; Hong ZY; Lin CS
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
